Key signalling pathways underlying the aetiology of polycystic ovary syndrome. Issue 1 (7th September 2022)

• Record Type: Journal Article
• Authors: Walters, Kirsty A; Moreno-Asso, Alba; Stepto, Nigel K; Pankhurst, Michael W; Rodriguez Paris, Valentina; Rodgers, Raymond J
• Is Part Of: Journal of endocrinology. Volume 255:Issue 1(2022)
• Page Start: R1
• Page End: R26
• Publication Date: 2022-09-07
• Subjects: androgen -- insulin -- anti-Müllerian hormone (AMH) -- transforming growth factor beta (TGFβ) -- polycystic ovary syndrome (PCOS); Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/JOE-22-0059
• Languages: English
• ISSNs: 0022-0795

Abstract

Abstract : Polycystic ovary syndrome (PCOS) is a common endocrine condition characterised by a range of reproductive, endocrine, metabolic and psychological abnormalities. Reports estimate that around 10% of women of reproductive age are affected by PCOS, representing a significant prevalence worldwide, which poses a high economic health burden. As the origin of PCOS remains largely unknown, there is neither a cure nor mechanism-based treatments leaving patient management suboptimal and focused solely on symptomatic treatment. However, if the underlying mechanisms underpinning the development of PCOS were uncovered then this would pave the way for the development of new interventions for PCOS. Recently, there have been significant advances in our understanding of the underlying pathways likely involved in PCOS pathogenesis. Key insights include the potential involvement of androgens, insulin, anti-Müllerian hormone and transforming growth factor beta in the development of PCOS. This review will summarise the significant scientific discoveries on these factors that have enhanced our knowledge of the mechanisms involved in the development of PCOS and discuss the impact these insights may have in shaping the future development of effective strategies for women with PCOS.